The Food and Drug Administration approved the first direct generic competitor to the EpiPen on Thursday, setting the stage for cheaper competition that may lower prices.
The new generic, which won’t carry the EpiPen name, will be made by Israeli generic manufacturer Teva Pharmaceuticals. It was approved after the FDA issued new guidance for generic copies of products like the EpiPen, which combines a drug with a specialized device to deliver it fast when people have life-threatening allergic reactions.
“This approval means patients living with severe allergies who require constant access to life-saving epinephrine should have a lower-cost option, as well as another approved product to help protect against potential drug shortages,” FDA Commissioner Dr. Scott Gottlieb said in a statement.
Click here for more.